Investigation of GLP-2 Mechanism of Action (GA-8)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-16

Study Completion Date

2017-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glucagon-like peptide-2 (GLP-2) is a naturally occuring hormone secreted to the circulation in response to food ingestion. Previous studies have shown that GLP-2 and incretins inhibit the bone resorption. However, the mechanism is unknown. In the present study we will investigate the mechanism of action using a receptor specific inhibitor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Gut Peptides on Bone Remodeling

NCT03574064

Healthy

COMPLETED NA

Gut Hormones and Bone Remodeling in Humans (KS-2)

NCT03573934

Healthy

COMPLETED NA

Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

NCT06774807

Healthy

COMPLETED NA

The Effect of GLP-1 on the Inhibition of Glucagon Secretion

NCT01507597

Type 2 Diabetes Type 1 Diabetes

COMPLETED NA

GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake

NCT02598791

Obesity Adiposity Type 2 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inhibitor + GLP-2

Group Type EXPERIMENTAL

Inhibitor + GLP-2

Intervention Type OTHER

Inhibitor and GLP-2 are used as study tools.

Placebo + GLP-2

Group Type EXPERIMENTAL

Placebo + GLP-2

Intervention Type OTHER

Placebo and GLP-2 are used as study tools.

Placebo + GIP

Group Type ACTIVE_COMPARATOR

Placebo + GIP

Intervention Type OTHER

Placebo and GIP are used as study tools.

Placebo + Saline

Group Type PLACEBO_COMPARATOR

Placebo + Saline

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inhibitor + GLP-2

Inhibitor and GLP-2 are used as study tools.

Intervention Type OTHER

Placebo + GLP-2

Placebo and GLP-2 are used as study tools.

Intervention Type OTHER

Placebo + GIP

Placebo and GIP are used as study tools.

Intervention Type OTHER

Placebo + Saline

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, 20 to 40 years old, caucasian, BMI 18,5 to 24,9 kg/m2

Exclusion Criteria

* Chronic disease, smoking, medication, weight change more than 3 kg whitin the last 3 months, overweight surgery, intestinal surgery, Hgb\<8,0 mmol/L, decreased renal function.

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes